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Abstract 
Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin 
lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in 
relation with clinical characteristics. CfDNA levels in cHL patients were significantly higher 
compared with controls (p=0.002). CfDNA at diagnosis was correlated with presence of B 
symptoms (p=0.027) and high erythrocyte sedimentation rate (p=0.049). We found that the in-
creasing of plasma cfDNA after first chemotherapy cycle seems to be associated with a worse 
prognosis (p=0.049). Levels of plasma cfDNA might constitute an interesting non-invasive tool in 
cHL patients’ management. 
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Introduction 
Classical Hodgkin lymphoma (cHL) is a malig-
nant disease of the lymphatic system, histologically 
characterized by multinuclear Hodgkin’s and 
Reed-Sternberg cells, that usually account for less 
than 1% of cells in the tumour tissue and are embed-
ded in a reactive infiltrate. Clinical trials have the goal 
of maintaining high cure rates while minimizing late 
effects by identification of patients who are most 
likely to benefit from reduced-intensity therapy. For 
this reason identification of biological parameters for 
monitoring disease during therapy and follow-up 
should be strongly required. 
Materials and Methods 
Peripheral blood samples of paediatric HL pa-
tients were collected from Associazione Italiana di 
Emato-Oncologia Pediatrica (A.I.E.O.P.) centers in the 
laboratory of Padua University in the period from 
December 1, 2004 to August, 31 2014. We evaluated 
cfDNA in plasma samples obtained at diagnosis (time 
point TP0) in a total of 155 cases: in 75/155 we also 
analyzed time-point TP1 (after the first chemotherapy 
cycle), in 41/155 TP2 (after stop chemotherapy) and in 
25/155 cases TP3 (after radiotherapy, if required by 
protocol).  
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Written consent was obtained from parents or 
legal guardians of each patient before enrolment. The 
study was approved by the ethics committee of each 
participating Institution. A control group of 15 pedi-
atric healthy individuals (7 males, 8 females; median 
12 yrs, range 5-16) was included to determine the 
normal range of circulating cfDNA in plasma. Pe-
ripheral blood samples in sodium citrate were pro-
cessed within 24 hours from drawing and plasma 
cfDNA was quantified using a Taq-Man based re-
al-time PCR assay for the POLR2 gene as previously 
reported [1]. Wilcoxon rank sum test was used to 
compare plasma levels between different patient 
subgroups and controls. Associations of cfDNA with 
specific clinical characteristics were tested with 
Chi-square test and Fisher’s exact test when appro-
priate.  
Results 
From 2004, in Italy, children and adolescents 
with cHL were enrolled in a multicenter clinical trial 
of A.I.E.O.P, namely AIEOP LH-2004. Patients, staged 
according to Ann Arbor classification [2], were allo-
cated to three different therapeutic groups, based on 
risk groups. In the present study, we investigated the 
presence of circulating cell-free DNA (cfDNA) in 
plasma at diagnosis and during chemotherapy of a 
large series of pediatric cHL patients and analyzed its 
association with clinical features. As cancer cells 
grow, nucleic acids are released into the bloodstream 
through apoptosis, necrosis or secretion [3,4]. Nucleid 
acids can be found also in small amounts in plasma of 
healthy individuals, however blood levels of cfDNA 
in plasma of patients with tumour are usually 2˜3 
times higher than in normal healthy subjects [5].  
The median age at diagnosis for 155 cHL patients 
was 13.6 years (range 2.7-19.7) and 51% (79/155) were 
females. The 2-year event free survival (± standard 
error, SE) and overall survival were 83% (± SE 4%) 
and 98% (± SE 2%) respectively. Patients who 
achieved clinical remission (complete or partial re-
mission>75%) were 134, while 21 patients had a re-
lapse or a progression (relapse was considered patho-
logically-confirmed recurrence of cHL, and progression 
the same condition diagnosed within 3 months of the 
end of therapy) at the median time of 0.85 year (range 
0.28-5.8 years) from diagnosis. Three patients out of 
155 died of progressive disease.  
The concentration of cfDNA in plasma samples 
at TP0 was significantly higher than in the controls 
(mean value 112 ng/mL in cHL cases versus 5.5 
ng/mL in healthy controls, p=0.002). We found that 
high cfDNA plasma concentrations at diagnosis cor-
related with presence of B symptoms (p=0.027) and 
high erythrocyte sedimentation rate (ESR) (p=0.049). 
No association was found between cfDNA levels and 
other clinical characteristics analyzed (gender, medi-
an age, stage, therapeutic group, bulky disease). Con-
sidering that B-symptoms are due to the production of 
pro-inflammatory cytokines by the Hodgkin tumor 
tissue and ESR is a marker of inflammatory reaction, 
we could speculate that in cHL patients high levels of 
cfDNA correlate with inflammatory status and dis-
ease activity. As observed in patients with colorectal 
cancer, most of cfDNA did not derive from the neo-
plastic cells themselves, but from engulfment by 
macrophages of neoplastic cells and surrounding 
stromal and inflammatory cells within the tumour [6]. 
This is particular interesting if we consider that HL is 
characterized by only a small fraction of tumor cells 
surrounded by a massive inflammatory infiltrate.  
Plasma cfDNA levels at time points TP1, TP2 
and TP3 were also quantified in an unselected sub-
group of our cHL cohort to evaluate the kinetics of 
this biological marker. Overall, a decrease of median 
cfDNA level was observed during chemotherapy 
treatment (TP0= 40 ng/mL; TP1= 22 ng/mL; TP2= 22 
ng/mL; TP3= 15 ng/mL). Of note, cfDNA increased 
of at least 1.5 times compared with diagnosis at TP1 in 
24/75 patients (32%) and we observed a significant 
correlation with mediastinal bulky involvement 
(p=0.03). In particular, 40/75 (53%) patients presented 
mediastinal bulky disease at diagnosis and in 45% 
(18/40) there was an increasing of cfDNA at TP1 
whereas, in the remaining 35/75 (47%) patients 
without mediastinal bulky disease at diagnosis, only 
17% (6/35) had a cfDNA increasing at TP1. We eval-
uated whether cases with increasing of cfDNA be-
tween the different time points (TP0 vs TP1; TP0 vs 
TP2; TP0 vs TP3; TP1 vs TP2; TP1 vs TP3; TP2 vs TP3) 
were associated to relapse/progression and we found 
that the increasing of cfDNA in TP1 compared to TP0 
was significantly associated to relapse/progression 
(p=0.049) (Fig.1). In particular, there was 20% of 
events in the subgroup of 24 patients with increasing 
cfDNA at TP1, versus 8% of events in the subgroup of 
51 patients with decreasing cfDNA at TP1 compared 
to TP0. 
Discussion  
Tumour specific molecular markers are im-
portant clinical tools for disease monitoring; in cHL 
the absence of these markers has always prevented 
this kind of investigation. Circulating cfDNA could 
not still be used as independent prognostic factor in 
cHL but, based on our data, it has to be considered for 
further analysis. Our study showed that in cHL of 
childhood and adolescence circulating plasma cfDNA 
at diagnosis correlate with a diffuse inflammatory 
status. Recently in adult cHL, Romano et al.[7] 
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showed that circulating myeloid-derived suppressor 
cells (MDSC) are increased at diagnosis and could 
predict short progression free survival. The accumu-
lation of MDSC is a hallmark of malignan-
cy-associated inflammation and T cell suppression in 
cancer [8]. However, the authors underlined that the 
use of MDSC as single biomarker is not sufficient be-
cause chronic inflammation status can trigger MDSC 
expansion and the intensive hematopoiesis during 
chemotherapy can favor MDSC release limiting their 
usage during treatment. In the next future, it could be 
very interesting to analyze, in pediatric patients, 
MDSC levels together with circulating cfDNA to 
evaluate if these two tumor inflammation markers are 
independent and could be used together in a 
risk-adapted therapeutic strategy.We found that the 
increasing of cfDNA after first chemotherapy cycle 
seems to be associated with a worse prognosis. To 
identify reliable parameters to predict the outcome in 
the single patient remains a challenge in pediatric 
oncology, but cfDNA study could play a significant 
role in this challenge for the next clinical trials in cHL. 
 
 
Figure 1. Distribution of plasma cfDNA during chemotherapy treatment 
in cHL patients who experienced relapse or progressive disease. The 
upper border of the box indicated the upper quartile (75th percentile) while 
the lower border indicate the lower quartile (25th percentile) and the 
horizontal line in the box the median. TP0= diagnosis; TP1=after 1st 
chemotherapy cycle; TP2= stop chemotherapy; TP3=after radiotherapy. 
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